IP Verse

Fixed Dosing Of Her Antibodies - EP1846030

EP1846030

GENENTECH
Application Number
EP05785414A
Filing Date
Jun 15, 2005
Status
Revoked
Jul 9, 2021
Grant Date
Nov 21, 2018
External Links
Slate, Register, Google Patents

Bibliography

The patent EP1846030B1 was granted to Genentech on Nov 21, 2018 following the initial filing on Jun 15, 2005 under the application number EP05785414A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEEMINGAug 21, 2019ADMISSIBLE
DR H ULRICH DORRIESAug 20, 2019WITHDRAWN
BREUERAug 19, 2019ADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEAug 15, 2019ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
INTERNATIONAL-SEARCH-REPORTWO0100238
OPPOSITIONEP1585966
OPPOSITIONEP1825001
OPPOSITIONWO0100245
OPPOSITIONWO2004008099
OPPOSITIONWO2006063042

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- BASELGA J ET AL, "PHASE II STUDY OF WEEKLY INTRAVENOUS RECOMBINANT HUMANIZED ANTI-P185HER2 MONOCLONAL ANTIBODY IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST CANCER", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, (199603), vol. 14, no. 3, ISSN 0732-183X, pages 737 - 744, XP000918166 [X] 1-4,9,13,15,16,18,19,21 * page 738, column R, paragraph 1 *-
INTERNATIONAL-SEARCH-REPORT- MALIK M A ET AL, "Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, (200307), vol. 44, ISSN 0197-016X, page 150, XP001246708 [X] 1-40 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- BASELGA J ET AL, "RECEPTOR BLOCKADE WITH MONOCLONAL ANTIBODIES AS ANTI-CANCER THERAPY", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, (1994), vol. 64, no. 1, ISSN 0163-7258, pages 127 - 154, XP009011842
INTERNATIONAL-SEARCH-REPORT- NG C ET AL, "Rationale for fixed dosing of pertuzumab by population pharmacokinetic (POP PK) modeling", CLINICAL PHARMACOLOGY & THERAPEUTICS, MOSBY-YEAR BOOK, ST LOUIS, MO, US, (20050205), vol. 77, no. 2, ISSN 0009-9236, page P33, XP004802442 [PX] 1-40 * the whole document *
INTERNATIONAL-SEARCH-REPORT- FRANKLIN MATTHEW C ET AL, "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex", CANCER CELL, (200404), vol. 5, no. 4, ISSN 1535-6108, pages 317 - 328, XP002372929
INTERNATIONAL-SEARCH-REPORT- BASELGA J, "Phase I and II clinical trials of trastuzumab", ANNALS OF ONCOLOGY 2001 NETHERLANDS, (2001), vol. 12, no. SUPPL. 1, ISSN 0923-7534, pages S49 - S55, XP009063466 [X] 1-4,9,13,15,16,18,19,21 * table 2 *
INTERNATIONAL-SEARCH-REPORT- LEYLAND-JONES BRIAN, "Dose scheduling-Herceptin(R)", ONCOLOGY (BASEL), (200110), vol. 61, no. Suppl 2, ISSN 0030-2414, pages 31 - 36, XP009063513
INTERNATIONAL-SEARCH-REPORT- AGUS D B ET AL, "PHASE I CLINICAL STUDY OF PERTUZUMAB, A NOVEL HER DIMERIZATION INHIBITOR, IN PATIENTS WITH ADVANCED CANCER", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, (20050410), vol. 23, no. 11, ISSN 0732-183X, pages 2534 - 2543, XP008058275 [PX] 1-40 * the whole document *
OPPOSITION- AGUS et al., "Clinical activity in a phase I trial of HER-2-targeted thuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST", Proc Am Soc Clin Oncol 22, (20030000), XP009070506-
OPPOSITION- AGUS et al., "Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth", Cancer Cell, (20020000), vol. 2, pages 127 - 137, XP002988666-
OPPOSITION- ALLISON et al., "Pharmacokinetics of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies: Phase la results", Proc Am Soc Clin Oncol, (20030000), vol. 22, XP009070554-
OPPOSITION- anonymous, "A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer", CLINICAL TRIALS.GOV NCT03674112, (20180917), XP055637538-
OPPOSITION- Anonymous, "Cellosaurus MDA-MB-175-VII (CVCL_1400)", SIB Swiss Institute of Bioinformatics, (20120404), URL: https://web.expasy.org/cellosaurus/CVCL_1400, XP055637594-
OPPOSITION- Anonymous, "Genentech reports additional data from BioOncology Pipeline at ASCO. Phase I data on Omnitarg (pertuzumab) in solid tumors and first study on Tarceva (erlotinib HG) and Avastin (bevacizumab) combination presented", Genentech Press Release, (20030601), URL: https://www.gene.com/media/press-releases/6228/2003-06-01/genentech-reports-additional-data-from-b, XP055637541-
OPPOSITION- BASELGA et al., "PHASE II STUDY OF WEEKLY INTRAVENOUS RECOMBINANT HUMANIZED ANTI-P185HER2 MONOCLONAL ANTIBODY IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST CANCER", JOURNAL OF CLINICAL ONCOLOGY, (19960300), vol. 14, no. 3, pages 737 - 744, XP000918166-
OPPOSITION- BOSSENMAIER et al., "Presence of HER2/HER3 heterodimers predicts antitumor effects of pertuzumab (Omnitarg) in different human xenograft models", Proc Amer Assoc Cancer Res, (20040300), vol. 45, page 1232, XP001538507-
OPPOSITION- BRITTEN, "TARGETING ERBB RECEPTOR SIGNALING: A PAN-ERBB APPROACH TO CANCER", Molecular Cancer Therapeutics, (200410), vol. 3, no. 10, pages 1335 - 1342, XP009058669-
OPPOSITION- CAILLEAU et al., "LONG-TERM HUMAN BREAST CARCINOMA CELL LINES OF MET ASTA TIC ORIGIN: PRELIMINARY CHARACTERIZATION", In Vitro, (19781100), vol. 14, no. 11, pages 911 - 915, XP055637573-
OPPOSITION- "Entry in the database ''REGISTRY'' of the database operator Chemical Abstracts Service (CAS", CAS, Database accession no. 180288-69-1-
OPPOSITION- FRIESS et al., "In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression", AACR NCI EORTC Mol Targets Cancer Ther, (20020000), XP055634671-
OPPOSITION- Genentech Reports Additional Data from BioOncology Pipeline at ASCO was published before the priority date and therefore is prior art according to Art. 54(2) EPC ., (20030000), XP055634655-
OPPOSITION- Information on the origin and nature of the cell line SK - BR -3 .-
OPPOSITION- LEWIS-PHILLIPS et al., "In vitro and in vivo efficacy of a novel HER2 antibody, rhuMAb 2C4, on human breast and lung tumor cells", Proc Annu Meet Am Assoc Cancer Res, (20020000), vol. 43, XP001525357-
OPPOSITION- MALIK et al., "Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models", Proc Am Assoc Cancer Res Annual Meeting, (20030700), vol. 44, page 150, XP001246708-
OPPOSITION- REGISTRY, Database accession no. 380610-27-5-
OPPOSITION- SPICE R, "Technology evaluation: Pertuzumab, Roche/Genentech/Chugai", (20040000), XP009058601-
OPPOSITION- SWANTON, "New targets and innovative strategies in cancer treatment: One year of progress", IDDB Meeting Report, Nice, France, (20040213), XP055634674-
OPPOSITION- "Tabelle 2, 3", ENGELHARDT et al., Endokrin-aktive maligne Tumoren, Springer-Verlag, (19870000), page 96, ISBN 978-3-540-16624-5, XP055637583-
OPPOSITION- VALERO et al., "Future direction of neoadjuvant therapy for breast cancer", Semin Oncol, (19980400), vol. 25, pages 36 - 41, XP055634677-
OPPOSITION- CORMACK P. L., "Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer", Drugs, (20130900), vol. 73, no. 13, pages 1491 - 1502, XP055637585
OPPOSITION- FRANKLIN et al., "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex", Cancer Cell, (20040400), vol. 5, no. 4, doi:10.1016/S1535-6108(04)00083-2, pages 317 - 328, XP002372929
OPPOSITION- BADACHE et al., "A new therapeutic antibody masks ErbB2 to its partners", Cancer Cell, (20040400), vol. 5, no. 4, pages 299 - 301, XP002378995
OPPOSITION- BASELGA et al., "PHASE I AND II CLINICAL TRIALS OF TRASTUZUMAB", Annals of Oncology, (20010000), vol. 12, pages S49 - S55, XP009063466
OPPOSITION- GSCHWIND et al., "The discovery of receptor tyrosine kinases: tar- gets for cancer therapy", NATURE REVIEWS CANCER, (20040500), vol. 4, no. 5, pages 361 - 370, XP008038394
OPPOSITION- SLAMON et al., "USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2", N Engl J Med, (20010315), vol. 344, no. 11, pages 783 - 792, XP008019806
OPPOSITION- SOULE et al., "A human cell line from a pleural effusion derived from a breast carcinoma", JNCI: J Nat Cancer Inst, (19730000), vol. 51, no. 5, pages 1409 - 1416, XP055634632
OPPOSITION- CAILLEAU et al., "Breast Tumor Cell Lines From Pleural Effusions", Journal of the National Cancer Institute, (19740900), vol. 53, no. 3, pages 661 - 674, XP055637566
OPPOSITION- NAHTA et al., "he HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells", Cancer Research, (20040400), vol. 64, pages 2324 - 2346, XP002521223
OPPOSITION- NAHTA et al., "The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells", Cancer Research, (20040000), vol. 64, doi:10.1158/0008-5472.CAN-03-3856, pages 2343 - 2346, XP002521223
OPPOSITION- NAHTA et al., "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", Cancer Research, (20040000), vol. 64, no. 7, pages 2343 - 2346, XP002378994
OPPOSITION- R. NAHTA et al., "The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells", Cancer Research, (20040000), vol. 64, doi:10.1158/0008-5472.CAN-03-3856, pages 2343 - 2346, XP002521223
OPPOSITION- BIANCO, "Targeting c-erbB2 and other receptors of the C-ErbB family: Rationale and clinical applications", Journal of Chemotherapy, (20040000), vol. 16, no. 4, pages 52 - 54, XP055634650
OPPOSITION- CORTES, "Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2", J Clin Oncol, (20050601), vol. 23, no. 16, XP055634622
OPPOSITION- GIANNI L. et al., "Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Per- tuzumab, a Human Epidermal Growth Factor Receptor 2 Dimeri- zation Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer", Journal of Clinical Oncology, (20100200), vol. 28, no. 7, pages 1131 - 1137, XP055252498
OPPOSITION- NAHTA et al., "Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention", The Oncologist, (20030201), vol. 8, no. 1, pages 5 - 17, XP055637555

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents